ARTICLE | Company News
4SC, Panoptes Pharma deal
September 30, 2013 7:00 AM UTC
Panoptes received rights to preclinical chronic uveitis and conjunctivitis compound PP-001 from 4SC's 4SC Discovery GmbH subsidiary. 4SC received a 24.9% stake in Panoptes and is eligible for milesto...